Eton Pharmaceuticals Stock Price, News & Analysis

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) announced its plan to release third quarter 2022 financial results on November 10, 2022. The management will host a conference call at 4:30 p.m. ET to discuss the results, with live audio accessible via the company's investor relations website. Participants are required to register for dial-in details, enhancing security and streamlining access. Eton specializes in developing treatments for rare diseases and currently has three FDA-approved products, along with several candidates in late-stage development.

Eton Pharmaceuticals (Nasdaq: ETON) announced that CEO Sean Brynjelsen will present at the LD Micro Main Event XV Conference on October 26, 2022, at 6:00 PM ET. The event will be available via webcast on the company's website in the Investors section. Eton focuses on developing treatments for rare diseases and currently markets ALKINDI SPRINKLE® and Carglumic Acid tablets, with several additional products under development. For more information, visit www.etonpharma.com.

Eton Pharmaceuticals (Nasdaq: ETON) announced the acquisition of betaine anhydrous for oral solution, enhancing its portfolio focused on rare diseases. This FDA-approved product targets fewer than 2,000 patients in the U.S. with a market estimated at $10 million annually. CEO Sean Brynjelsen highlighted that the acquisition is expected to be accretive to 2023 earnings and aligns with their strategy to commercialize treatments for underserved populations. Eton plans to integrate the product later this year.

Eton Pharmaceuticals (Nasdaq: ETON) announced that CEO Sean Brynjelsen will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 1:30 PM ET. The presentation will be available via webcast on the company's investor relations website. Eton focuses on developing treatments for rare diseases and currently markets products like ALKINDI SPRINKLE® and Carglumic Acid tablets. The company has additional rare disease products in development and is entitled to milestone payments or royalties on several products.

Eton Pharmaceuticals reported Q2 2022 revenue of $7.4 million, a 139% increase from the previous year. The company completed the divestiture of its hospital products division, focusing solely on rare diseases. Key growth drivers included ALKINDI SPRINKLE®, which saw 293% year-over-year growth, and Carglumic Acid, with a 100% sequential increase in sales. The FDA approved Zonisade™, with a $5 million milestone payment expected upon launch. Net loss for the quarter was $1.6 million.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) will report its second quarter 2022 financial results on August 11, 2022. A conference call and audio webcast will be held at 4:30 p.m. ET, featuring a Q&A session for investors. Eton specializes in developing treatments for rare diseases, currently marketing ALKINDI SPRINKLE® and Carglumic Acid tablets, and has additional products under development. The company also receives royalties from seven other products. Interested investors can access the live webcast on Eton's website.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) announced FDA approval for ZONISADE™ (zonisamide oral suspension) on July 18, 2022. This marks the eighth product approval for Eton's development team. ZONISADE™ will be commercialized by Azurity Pharmaceuticals, resulting in a $5 million milestone payment to Eton, along with royalties on net sales and potential commercial milestones totaling up to $15 million. The funds from this launch will help expand Eton's rare disease portfolio.

Dr. Reddy’s Laboratories has acquired a portfolio of branded and generic injectable products from Eton Pharmaceuticals for approximately $5 million upfront, with potential contingent payments of $45 million. The acquisition includes the NDAs for Biorphen® and Rezipres® injections and aims to enhance Dr. Reddy’s institutional business in the U.S. market, where the total addressable market for these products is estimated at $174 million for the year ending April 2022. This move supports Dr. Reddy’s commitment to expanding affordable medications.

Eton Pharmaceuticals has sold its rights to Biorphen®, Rezipres®, and Cysteine Hydrochloride products to Dr. Reddy's Laboratories for potential payments of up to $50 million. This strategic move allows Eton to concentrate on its core business of rare disease treatments. Eton's royalty portfolio is set to earn up to $70 million from milestone payments and royalties on additional products. The company retains its focus on four rare disease candidates, enhancing its position in the pharmaceutical market aimed at underserved conditions.